Treatment with obinutuzumab-chlorambucil , as compared with rituximab-chlorambucil , resulted in prolongation of progression-free survival ( hazard ratio , @ ; @ % CI , @ to @ ; P < @ ) and higher rates of complete response ( @ % vs. @ % ) and molecular response .